MedTrace Logo

Efficacy and Safety of DHEA for Myotonic Dystrophy

NCT00167609 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-04-06

No results posted yet for this study

Summary

To test the efficacy and safety of two doses of dehydroepiandrosterone (DHEA) in adults with myotonic dystrophy

Conditions

  • Myotonic Dystrophy

Interventions

DRUG

dehydroepiandrosterone 100 and 400 mg

Sponsors & Collaborators

  • Association Française contre les Myopathies (AFM), Paris

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • University of Versailles

    lead OTHER

Principal Investigators

  • Djillali annane, MD, PhD · Assistance Publique Hôpitaux de Paris - University of Versailles

  • martine devillers, MD · AFM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2006-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167609 on ClinicalTrials.gov